.jpg)
Patient Friendly Audio discussing interferon-free regimens for the treatment of HCV
So grab a few wings, sit back and listen to Dr. Mark Sulkowski summarize treatment considerations for hepatitis C patients using new interferon-free regimens based on AASLD/IDSA joint guidelines, launched yesterday over at Clinical Care Options (CCO).
Not To Be Missed
The good doctor follows up the program with an in-depth question and answer session.
Key Points
Peginterferon is no longer a first line therapy for any patient.
We now have three FDA approved interferon free regimens for genotype 1.
No differences in how we treat co-infected patients with HIV compared to mono-infected except for the point of drug interactions.
Highlights
Treatment in genotype 1a and 1b.
Treatment duration
Treatment with or without ribavirin for both treatment experienced or treatment naive patients.
Treatment for patients with or without cirrhosis.
Treatment in liver transplantation patients.
Summary Of Questions
Biggest HCV cure is patient adherence
Duration of therapy for patients with cirrhosis
Monitoring patients who achieve SVR for liver cancer.
Staging fibrosis
Current recommendations in treating Genotype 3.
Initiating treatment, wait or treat.
Resistance testing
and more.....
Free registration is available, here.
Incorporating the Latest AASLD/IDSA Guidance on HCV Management
Source: HCV Alerts: Rapid Response to Practice-Changing Advances
Treatment with or without ribavirin for both treatment experienced or treatment naive patients.
Treatment for patients with or without cirrhosis.
Treatment in liver transplantation patients.
Biggest HCV cure is patient adherence
Duration of therapy for patients with cirrhosis
Monitoring patients who achieve SVR for liver cancer.
Staging fibrosis
Current recommendations in treating Genotype 3.
Initiating treatment, wait or treat.
Resistance testing
and more.....
Free registration is available, here.
Incorporating the Latest AASLD/IDSA Guidance on HCV Management
Source: HCV Alerts: Rapid Response to Practice-Changing Advances
Expert Highlight
Dr. Mark Sulkowski discusses how to incorporate the latest AASLD/IDSA guidance on HCV management into clinical practice. (30 Minutes)
Format: mp3
File size: 21.69 MB
Date posted: 1/30/2015
Slideset
In this downloadable slideset, Dr. Mark Sulkowski highlights how to incorporate the latest AASLD/IDSA guidance on HCV into clinical practice.
Format: Microsoft PowerPoint (.ppt)
File size: 565 KB
Date posted: 1/20/2015
Enjoy the game tomorrow!
Tina
No comments:
Post a Comment